Rogocekib
- Generic Name
- Rogocekib
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Phase 1
Recruiting
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Chordia Therapeutics, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT05732103
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath